Global pharmaceutical company Lupin Limited has announced the appointment of Anand Kripalu to its Board of Directors as an Independent Director, effective February 13, 2026. Mr. Kripalu brings over three decades of extensive leadership experience, primarily from the Fast-Moving Consumer Goods (FMCG) sector, including top roles at EPL Limited, Diageo India, and Mondelez International. The Chairman expressed confidence that his experience will be invaluable in advancing Lupin’s strategic goals in the global pharmaceutical industry.
Lupin Welcomes Anand Kripalu to the Board
Lupin Limited, a major global pharmaceutical firm headquartered in Mumbai, officially announced on February 13, 2026, the induction of Anand Kripalu as an Independent Director to its Board. This appointment leverages Mr. Kripalu’s significant leadership background spanning more than three decades, primarily within the fast-moving consumer goods (FMCG) sector.
Distinguished Leadership Background
Mr. Kripalu currently serves as the Executive Director of EPL Limited and was previously its Managing Director and Global CEO until December 31, 2025. His prior distinguished roles include leading Diageo India as Managing Director and CEO, and serving as President – India and South-East Asia at Mondelez International (Cadbury). Earlier in his career, he spent over 20 years at Unilever in various senior management, sales, and marketing capacities across different geographies.
Educational Credentials and Current Commitments
Anand Kripalu holds a B.Tech in Electronics from IIT Madras and an MBA from IIM Calcutta, having received the Distinguished Alumnus Award from both institutions. He has also completed the Advanced Management Program at Wharton Business School. Furthermore, he currently serves as an Independent Director on the boards of Swiggy Limited and United Breweries Limited, having previously been a director at Marico Limited.
Statement from Leadership
Manju D Gupta, Chairman of Lupin, welcomed the new addition, stating, “We are delighted to welcome Anand to the Board. His vast experience will be invaluable in advancing Lupin’s strategic priorities and reinforcing our position in the global pharmaceutical industry.”
About Lupin
Lupin Limited is a global pharmaceutical leader distributing products across more than 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs). Lupin maintains a strong presence in India and the U.S. across key therapeutic areas, supported by 15 state-of-the-art manufacturing sites and 7 research centers globally, employing a workforce exceeding 23,000 professionals.
Source: BSE
